A Review of Past and Present Weight Loss Strategies and the Potential Role of Bariatric Arterial Embolization

Abstract

The obesity epidemic is a growing public health concern that has a severe effect on the health care system with significant morbidity, mortality, and cost. Treatment options for obesity include lifestyle modifications, pharmacotherapy, and bariatric surgery. Newer, less-invasive therapies including endoscopic bariatric procedures have been developed in recent years to fill the treatment gap that exists between noninvasive approaches and surgery. Bariatric artery embolization (BAE) is a novel minimally invasive endovascular procedure that has been developed to treat obesity. Recent evidence has suggested that bariatric embolization is well tolerated and can induce clinically significant weight loss through a hormonally mediated mechanism. This article will review existing preclinical and clinical data, and explore future directions of the endovascular treatment of obesity.

Keywords

bariatric arterial embolization - BAE - weight loss - gastric artery - embolization

• References

• 1 Mitchell NS, Catenacci VA, Wyatt HR, Hill JO. Obesity: overview of an epidemic. Psychiatr Clin North Am 2011; 34 (04) 717-732
• 2 Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity among adults and youth: United States, 2015–2016. NCHS Data Brief 2017; (288) 1-8
• 3 James WPT. WHO recognition of the global obesity epidemic. Int J Obes 2008; 32 (Suppl. 07) S120-S126
• 4 Pantalone KM, Hobbs TM, Chagin KM. , et al. Prevalence and recognition of obesity and its associated comorbidities: cross-sectional analysis of electronic health record data from a large US integrated health system. BMJ Open 2017; 7 (11) e017583
• 5 Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health 2009; 9 (01) 88
• 6 Khaodhiar L, McCowen KC, Blackburn GL. Obesity and its comorbid conditions. Clin Cornerstone 1999; 2 (03) 17-31
• 7 Upadhyay J, Farr O, Perakakis N, Ghaly W, Mantzoros C. Obesity as a disease. Med Clin North Am 2018; 102 (01) 13-33
• 8 Dawes AJ, Maggard-Gibbons M, Maher AR. , et al. Mental health conditions among patients seeking and undergoing bariatric surgery a meta-analysis. JAMA 2016; 315 (02) 150-163
• 9 Rotenberg KJ, Bharathi C, Davies H, Finch T. Obesity and the social withdrawal syndrome. Eat Behav 2017; 26: 167-170
• 10 Marek RJ, Heinberg LJ, Lavery M, Merrell Rish J, Ashton K. A review of psychological assessment instruments for use in bariatric surgery evaluations. Psychol Assess 2016; 28 (09) 1142-1157
• 11 Puhl RM, Wall MM, Chen C, Bryn Austin S, Eisenberg ME, Neumark-Sztainer D. Experiences of weight teasing in adolescence and weight-related outcomes in adulthood: a 15-year longitudinal study. Prev Med 2017; 100: 173-179
• 12 Haines J, Hannan PJ, van den Berg P, Eisenberg ME, Neumark-Sztainer D. Weight-related teasing from adolescence to young adulthood: longitudinal and secular trends between 1999 and 2010. Obesity (Silver Spring) 2013; 21 (09) E428-E434
• 13 Finkelstein EA, Trogdon JG, Cohen JW, Dietz W. Annual medical spending attributable to obesity: payer-and service-specific estimates. Health Aff (Millwood) 2009; 28 (05) w822-w831
• 14 Wadden TA, Webb VL, Moran CH, Bailer BA. Lifestyle modification for obesity: new developments in diet, physical activity, and behavior therapy. Circulation 2012; 125 (09) 1157-1170
• 15 Franz MJ, Boucher JL, Rutten-Ramos S, VanWormer JJ. Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials. J Acad Nutr Diet 2015; 115 (09) 1447-1463
• 16 Stoner L, Rowlands D, Morrison A. , et al. Efficacy of exercise intervention for weight loss in overweight and obese adolescents: meta-analysis and implications. Sports Med 2016; 46 (11) 1737-1751
• 17 Olson K, Bond D, Wing RR. Behavioral approaches to the treatment of obesity. R I Med J (2013) 1996; 100 (02) 21-24
• 18 Anderson JW, Konz EC, Frederich RC, Wood CL. Long-term weight-loss maintenance : a meta-analysis of US studies. Am J Clin Nutr 2001; 100 (02) 21-24
• 19 Feinle-Bisset C. Modulation of hunger and satiety: hormones and diet. Curr Opin Clin Nutr Metab Care 2014; 17 (05) 458-464
• 20 Larder R, O'Rahilly S. Shedding pounds after going under the knife: guts over glory-why diets fail. Nat Med 2012; 18 (05) 666-667
• 21 Sumithran P, Prendergast LA, Delbridge E. , et al. Long-term persistence of hormonal adaptations to weight loss. Obstet Gynecol Surv 2012; 67 (02) 91-92
• 22 Melby CL, Paris HL, Foright RM, Peth J. Attenuating the biologic drive for weight regain following weight loss: Must what goes down always go back up?. Nutrients 2017; 9 (05) E468
• 23 Rosenbaum M, Hirsch J, Gallagher DA, Leibel RL. Long-term persistence of adaptive thermogenesis in subjects who have maintained a reduced body weight. Am J Clin Nutr 2008; 88 (04) 906-912
• 24 Khera R, Murad MH, Chandar AK. , et al. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA 2016; 315 (22) 2424-2434
• 25 Jensen MD, Ryan DH, Apovian CM. , et al; American Heart Association; American College of Cardiology; Obesity Society. Reprint: 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults. J Am Pharm Assoc (2003) 2014; 54 (01) e3
• 26 U.S. Department of Health and Human Services; Food and Drug Administration; Centre for drug Evaluation and Research. Guidance for industry: developing products for weight management (draft guidance). Available at: https://www.fda.gov/media/71252/download . Accessed April 16, 2020
• 27 Srivastava G, Apovian CM. Current pharmacotherapy for obesity. Nat Rev Endocrinol 2018; 14 (01) 12-24
• 28 Henness S, Perry CM. Orlistat: a review of its use in the management of obesity. Drugs 2006; 66 (12) 1625-1656
• 29 Apovian CM, Aronne LJ, Bessesen DH. , et al; Endocrine Society. Pharmacological management of obesity: an endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2015; 100 (02) 342-362
• 30 Patel D. Pharmacotherapy for the management of obesity. Metabolism 2015; 64 (11) 1376-1385
• 31 Greenway FL, Fujioka K, Plodkowski RA. , et al; COR-I Study Group. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010; 376 (9741): 595-605
• 32 Apovian CM, Aronne L, Rubino D. , et al; COR-II Study Group. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring) 2013; 21 (05) 935-943
• 33 Wadden TA, Foreyt JP, Foster GD. , et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring) 2011; 19 (01) 110-120
• 34 Hollander P, Gupta AK, Plodkowski R. , et al; COR-Diabetes Study Group. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care 2013; 36 (12) 4022-4029
• 35 Sharfstein JM, Psaty BM. Evaluation of the cardiovascular risk of naltrexone-bupropion: A study interrupted. JAMA 2016; 315 (10) 984-986
• 36 Verpeut JL, Bello NT. Drug safety evaluation of naltrexone/bupropion for the treatment of obesity. Expert Opin Drug Saf 2014; 13 (06) 831-841
• 37 Ladenheim EE. Liraglutide and obesity: a review of the data so far. Drug Des Devel Ther 2015; 9: 1867-1875
• 38 Wittert G, Caterson I, Finer N. The clinical effectiveness of weight loss drugs. Obes Res Clin Pract 2007; 1 (01) 1-78
• 39 Picot J, Jones J, Colquitt JL. , et al. The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation. Health Technol Assess 2009; 13 (41) 1-190 , 215–357, iii–iv
• 40 Colquitt JL, Pickett K, Loveman E, Frampton GK. Surgery for weight loss in adults. Cochrane Database Syst Rev 2014; 2014 (08) CD003641
• 41 Sjöström L, Narbro K, Sjöström CD. , et al; Swedish Obese Subjects Study. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357 (08) 741-752
• 42 Karmali S, Johnson Stoklossa C, Sharma A. , et al. Bariatric surgery: a primer. Can Fam Physician 2010; 56 (09) 873-879
• 43 Nguyen NT, Varela JE. Bariatric surgery for obesity and metabolic disorders: state of the art. Nat Rev Gastroenterol Hepatol 2017; 14 (03) 160-169
• 44 Coleman KJ, Fischer H, Arterburn DE. , et al. Effectiveness of gastric bypass versus gastric sleeve for cardiovascular disease: protocol and baseline results for a comparative effectiveness study. JMIR Res Protoc 2020; 9 (04) e14936
• 45 Kalinowski P, Paluszkiewicz R, Wróblewski T. , et al. Ghrelin, leptin, and glycemic control after sleeve gastrectomy versus Roux-en-Y gastric bypass-results of a randomized clinical trial. Surg Obes Relat Dis 2017; 13 (02) 181-188
• 46 Karamanakos SN, Vagenas K, Kalfarentzos F, Alexandrides TK. Weight loss, appetite suppression, and changes in fasting and postprandial ghrelin and peptide-YY levels after Roux-en-Y gastric bypass and sleeve gastrectomy: a prospective, double blind study. Ann Surg 2008; 247 (03) 401-407
• 47 Ponce J, Nguyen NT, Hutter M, Sudan R, Morton JM. American Society for Metabolic and Bariatric Surgery estimation of bariatric surgery procedures in the United States, 2011-2014. Surg Obes Relat Dis 2015; 11 (06) 1199-1200
• 48 Elder KA, Wolfe BM. Bariatric surgery: a review of procedures and outcomes. Gastroenterology 2007; 132 (06) 2253-2271
• 49 Hammond RA, Levine R. The economic impact of obesity in the United States. Diabetes Metab Syndr Obes 2010; 3: 285-295
• 50 Mahawar KK, Sharples AJ. Contribution of malabsorption to weight loss after Roux-en-Y gastric bypass: a systematic review. Obes Surg 2017; 27 (08) 2194-2206
• 51 Nelson DW, Blair KS, Martin MJ. Analysis of obesity-related outcomes and bariatric failure rates with the duodenal switch vs gastric bypass for morbid obesity. Arch Surg 2012; 147 (09) 847-854
• 52 Strain GW, Torghabeh MH, Gagner M. , et al. The impact of biliopancreatic diversion with duodenal switch (BPD/DS) over 9 years. Obes Surg 2017; 27 (03) 787-794
• 53 Buchwald H, Avidor Y, Braunwald E. , et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004; 292 (14) 1724-1737
• 54 O'Brien PE, Brown WA, Smith A, McMurrick PJ, Stephens M. Prospective study of a laparoscopically placed, adjustable gastric band in the treatment of morbid obesity. Br J Surg 1999; 86 (01) 113-118
• 55 Puzziferri N, Roshek III TB, Mayo HG, Gallagher R, Belle SH, Livingston EH. Long-term follow-up after bariatric surgery: a systematic review. JAMA 2014; 312 (09) 934-942
• 56 Kindel T, Martin E, Hungness E, Nagle A. High failure rate of the laparoscopic-adjustable gastric band as a primary bariatric procedure. Surg Obes Relat Dis 2014; 10 (06) 1070-1075
• 57 Altieri MS, Yang J, Telem DA. , et al. Lap band outcomes from 19,221 patients across centers and over a decade within the state of New York. Surg Endosc 2016; 30 (05) 1725-1732
• 58 Chang SH, Stoll CRT, Song J, Varela JE, Eagon CJ, Colditz GA. The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003-2012. JAMA Surg 2014; 149 (03) 275-287
• 59 Montero PN, Stefanidis D, Norton HJ, Gersin K, Kuwada T. Reported excess weight loss after bariatric surgery could vary significantly depending on calculation method: a plea for standardization. Surg Obes Relat Dis 2011; 7 (04) 531-534
• 60 Madsbad S, Dirksen C, Holst JJ. Mechanisms of changes in glucose metabolism and bodyweight after bariatric surgery. Lancet Diabetes Endocrinol 2014; 2 (02) 152-164
• 61 Chandarana K, Batterham RL. Shedding pounds after going under the knife: metabolic insights from cutting the gut. Nat Med 2012; 18 (05) 668-669
• 62 Karra E, Yousseif A, Batterham RL. Mechanisms facilitating weight loss and resolution of type 2 diabetes following bariatric surgery. Trends Endocrinol Metab 2010; 21 (06) 337-344
• 63 Batterham RL, Cummings DE. Mechanisms of diabetes improvement following bariatric/metabolic surgery. Diabetes Care 2016; 39 (06) 893-901
• 64 de Luis D, Domingo M, Romero A. , et al. Effects of duodenal-jejunal exclusion on beta cell function and hormonal regulation in Goto-Kakizaki rats. Am J Surg 2012; 204 (02) 242-247
• 65 Chambers AP, Jessen L, Ryan KK. , et al. Weight-independent changes in blood glucose homeostasis after gastric bypass or vertical sleeve gastrectomy in rats. Gastroenterology 2011; 141 (03) 950-958
• 66 Breen DM, Rasmussen BA, Kokorovic A, Wang R, Cheung GWC, Lam TKT. Jejunal nutrient sensing is required for duodenal-jejunal bypass surgery to rapidly lower glucose concentrations in uncontrolled diabetes. Nat Med 2012; 18 (06) 950-955
• 67 Peterli R, Wölnerhanssen B, Peters T. , et al. Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial. Ann Surg 2009; 250 (02) 234-241
• 68 Beckman LM, Beckman TR, Earthman CP. Changes in gastrointestinal hormones and leptin after Roux-en-Y gastric bypass procedure: a review. J Am Diet Assoc 2010; 110 (04) 571-584
• 69 Ramón JM, Salvans S, Crous X. , et al. Effect of Roux-en-Y gastric bypass vs sleeve gastrectomy on glucose and gut hormones: a prospective randomised trial. J Gastrointest Surg 2012; 16 (06) 1116-1122
• 70 Peterli R, Steinert RE, Woelnerhanssen B. , et al. Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial. Obes Surg 2012; 22 (05) 740-748
• 71 Westerveld D, Yang D. Through thick and thin: identifying barriers to bariatric surgery, weight loss maintenance, and tailoring obesity treatment for the Future. Surg Res Pract 2016; 2016: 8616581
• 72 Weiner JP, Goodwin SM, Chang HY. , et al. Impact of bariatric surgery on health care costs of obese persons: a 6-year follow-up of surgical and comparison cohorts using health plan data. JAMA Surg 2013; 148 (06) 555-562
• 73 Maciejewski ML, Livingston EH, Smith VA, Kahwati LC, Henderson WG, Arterburn DE. Health expenditures among high-risk patients after gastric bypass and matched controls. Arch Surg 2012; 147 (07) 633-640
• 74 Gulliford MC, Charlton J, Prevost T. , et al. Costs and outcomes of increasing access to bariatric surgery: cohort study and cost-effectiveness analysis using electronic health records. Value Health 2017; 20 (01) 85-92
• 75 Sarwer DB, Ritter S, Wadden TA, Spitzer JC, Vetter ML, Moore RH. Attitudes about the safety and efficacy of bariatric surgery among patients with type 2 diabetes and a body mass index of 30-40 kg/m2. Surg Obes Relat Dis 2013; 9 (05) 630-635
• 76 Yorke E, Switzer NJ, Reso A. , et al. Intragastric Balloon for Management of Severe Obesity: a Systematic Review. Obes Surg 2016; 26 (09) 2248-2254
• 77 Kotzampassi K, Grosomanidis V, Papakostas P, Penna S, Eleftheriadis E. 500 intragastric balloons: what happens 5 years thereafter?. Obes Surg 2012; 22 (06) 896-903
• 78 Haddad AE, Rammal MO, Soweid A. , et al. Intragastric balloon treatment of obesity: Long-term results and patient satisfaction. Turk J Gastroenterol 2019; 30 (05) 461-466
• 79 Saruç M, Böler D, Karaarslan M. , et al. Intragastric balloon treatment of obesity must be combined with bariatric surgery: a pilot study in Turkey. Turk J Gastroenterol 2010; 21 (04) 333-337
• 80 Dumonceau J-M. Evidence-based review of the Bioenterics intragastric balloon for weight loss. Obes Surg 2008; 18 (12) 1611-1617
• 81 Sullivan S. Aspiration Therapy for Obesity. Gastrointest Endosc Clin N Am 2017; 27 (02) 277-288
• 82 Thompson CC, Dayyeh BKA, Kushner R. , et al. 381 The AspireAssist is an effective tool in the treatment of class II and class III obesity: results of a one-year clinical trial. Gastroenterology 2016; 150 (04) (Suppl. 01) S86
• 83 Norén E, Forssell H. Aspiration therapy for obesity; a safe and effective treatment. BMC Obes 2016; 3 (01) 56
• 84 Jain D, Bhandari BS, Arora A, Singhal S. Endoscopic sleeve gastroplasty- A new tool to manage obesity. Clin Endosc 2017; 50 (06) 552-561
• 85 Vargas EJ, Rizk M, Bazerbachi F, Abu Dayyeh BK. Medical devices for obesity treatment: endoscopic bariatric therapies. Med Clin North Am 2018; 102 (01) 149-163
• 86 Sandler BJ, Rumbaut R, Swain CP. , et al. One-year human experience with a novel endoluminal, endoscopic gastric bypass sleeve for morbid obesity. Surg Endosc 2015; 29 (11) 3298-3303
• 87 de Lartigue G. Role of the vagus nerve in the development and treatment of diet-induced obesity. J Physiol 2016; 594 (20) 5791-5815
• 88 Johannessen H, Revesz D, Kodama Y. , et al. Vagal Blocking for Obesity Control: a Possible Mechanism-Of-Action. Obes Surg 2017; 27 (01) 177-185
• 89 Shikora SA, Wolfe BM, Apovian CM. , et al. Sustained weight loss with vagal nerve blockade but not with sham: 18-month results of the ReCharge trial. J Obes 2015; 2015: 365604
• 90 Shikora SA, Toouli J, Herrera MF. , et al. Intermittent vagal nerve block for improvements in obesity, cardiovascular risk factors, and glycemic control in patients with type 2 diabetes mellitus: 2-year results of the VBLOC DM2 study. Obes Surg 2016; 26 (05) 1021-1028
• 91 Apovian CM, Shah SN, Wolfe BM. , et al. Two-year outcomes of vagal nerve blocking (vbloc) for the treatment of obesity in the ReCharge trial. Obes Surg 2017; 27 (01) 169-176
• 92 Prologo J, Lin EA, Singh J. , et al. Abstract no. 577 percutaneous CT-guided cryoablation of the posterior vagal trunk for management of mild to moderate obesity: a pilot trial. J Vasc Interv Radiol 2018; 29 (04) S241-S242
• 93 Arepally A, Barnett BP, Montgomery E, Patel TH. Catheter-directed gastric artery chemical embolization for modulation of systemic ghrelin levels in a porcine model: initial experience. Radiology 2007; 244 (01) 138-143
• 94 Arepally A, Barnett BP, Patel TH. , et al. Catheter-directed gastric artery chemical embolization suppresses systemic ghrelin levels in porcine model. Radiology 2008; 249 (01) 127-133
• 95 Paxton BE, Kim CY, Alley CL. , et al. Bariatric embolization for suppression of the hunger hormone ghrelin in a porcine model. Radiology 2013; 266 (02) 471-479
• 96 Bawudun D, Xing Y, Liu WY. , et al. Ghrelin suppression and fat loss after left gastric artery embolization in canine model. Cardiovasc Intervent Radiol 2012; 35 (06) 1460-1466
• 97 Kim JM, Kim MD, Han K. , et al. Bariatric arterial embolization with non-spherical polyvinyl alcohol particles for ghrelin suppression in a swine model. Cardiovasc Intervent Radiol 2017; 40 (05) 744-749
• 98 Paxton BE, Alley CL, Crow JH. , et al. Histopathologic and immunohistochemical sequelae of bariatric embolization in a porcine model. J Vasc Interv Radiol 2014; 25 (03) 455-461
• 99 Paxton BE, Arepally A, Alley CL, Kim CY. Bariatric embolization: pilot study on the impact of gastroprotective agents and arterial distribution on ulceration risk and efficacy in a porcine model. J Vasc Interv Radiol 2016; 27 (12) 1923-1928
• 100 Fu Y, Weiss CR, Paudel K. , et al. Bariatric arterial embolization: effect of microsphere size on the suppression of fundal ghrelin expression and weight change in a swine model. Radiology 2018; 289 (01) 83-89
• 101 Diana M, Pop R, Beaujeux R. , et al. Embolization of arterial gastric supply in obesity (EMBARGO): an endovascular approach in the management of morbid obesity. proof of the concept in the porcine model. Obes Surg 2015; 25 (03) 550-558
• 102 Goitein D, Lederfein D, Tzioni R, Berkenstadt H, Venturero M, Rubin M. Mapping of ghrelin gene expression and cell distribution in the stomach of morbidly obese patients--a possible guide for efficient sleeve gastrectomy construction. Obes Surg 2012; 22 (04) 617-622
• 103 Swaby H, Gregory NG. A note on the frequency of gastric ulcers detected during post-mortem examination at a pig abattoir. Meat Sci 2012; 90 (01) 269-271
• 104 Pasciak AS, Bourgeois AC, Paxton BE. , et al. Bariatric radioembolization: a pilot study on technical feasibility and safety in a porcine model. J Vasc Interv Radiol 2016; 27 (10) 1509-1517
• 105 Vairavamurthy J, Anders R, Kraitchman D, Arepally A, Weiss C. 3:36 PM Abstract No. 105 Target vessel size for bariatric embolization: a comparative histologic evaluation of swine and human fundi. J Vasc Interv Radiol 2018; 29 (04) S48-S49
• 106 Gunn AJ, Weiss CR. Is There a Role for Bariatric Embolization in the Treatment of the Diabetic Patient?. J Vasc Interv Radiol 2019; 30 (06) 797-800
• 107 Anton K, Rahman T, Bhanushali A, Patel AA. Bariatric left gastric artery embolization for the treatment of obesity: a review of gut hormone involvement in energy homeostasis. AJR Am J Roentgenol 2016; 206 (01) 202-210
• 108 Kim DJ, Raman HS, Salter A. , et al. Analysis of weight changes after left gastric artery embolization in a cancer-naive population. Diagn Interv Radiol 2018; 24 (02) 94-97
• 109 Takahashi EA, Takahashi N, Reisenauer CJ, Moynagh MR, Misra S. Body composition changes after left gastric artery embolization in overweight and obese individuals. Abdom Radiol (NY) 2019; 44 (07) 2627-2631
• 110 Elens S, Roger T, Elens M. , et al. Gastric embolization as treatment for overweight patients; efficacy and safety. Cardiovasc Intervent Radiol 2019; 42 (04) 513-519
• 111 Kipshidze N, Archvadze A, Bertog S, Leon MB, Sievert H. Endovascular bariatrics: first in humans study of gastric artery embolization for weight Loss. JACC Cardiovasc Interv 2015; 8 (12) 1641-1644
• 112 Syed MI, Morar K, Shaikh A. , et al. Gastric artery embolization trial for the lessening of appetite nonsurgically (GET LEAN): six-month preliminary data. J Vasc Interv Radiol 2016; 27 (10) 1502-1508
• 113 Bai Z-B, Qin Y-L, Deng G, Zhao G-F, Zhong B-Y, Teng G-J. Bariatric embolization of the left gastric arteries for the treatment of obesity: 9-month data in 5 patients. Obes Surg 2018; 28 (04) 907-915
• 114 Pirlet C, Ruzsa Z, Costerousse O. , et al. Transradial left gastric artery embolization to treat severe obesity: A pilot study. Catheter Cardiovasc Interv 2019; 93 (03) 365-370
• 115 Zaitoun MMA, Basha MAA, Hassan F. , et al. Left gastric artery embolization in obese, prediabetic patients: a pilot study. J Vasc Interv Radiol 2019; 30 (06) 790-796
• 116 Weiss CR, Abiola GO, Fischman AM. , et al. Bariatric embolization of arteries for the treatment of obesity (BEAT Obesity) trial: results at 1 year. Radiology 2019; 291 (03) 792-800
• 117 Hafezi-Nejad N, Bailey CR, Gunn AJ, Weiss CR. Weight loss after left gastric artery embolization: a systematic review and meta-analysis. J Vasc Interv Radiol 2019; 30 (10) 1593-1603.e3
• 118 Lerner H, Whang J, Nipper R. Benefit-risk paradigm for clinical trial design of obesity devices: FDA proposal. Surg Endosc 2013; 27 (03) 702-707
• 119 Cummings DE, Arterburn DE, Westbrook EO. , et al. Gastric bypass surgery vs intensive lifestyle and medical intervention for type 2 diabetes: the CROSSROADS randomised controlled trial. Diabetologia 2016; 59 (05) 945-953
• 120 Pulkkinen L, Ukkola O, Kolehmainen M, Uusitupa M. Ghrelin in diabetes and metabolic syndrome. Int J Pept 2010; 2010: 1-11
• 121 Salsamendi J, Pereira K, Kang K, Fan J. Minimally invasive percutaneous endovascular therapies in the management of complications of non-alcoholic fatty liver disease (NAFLD): A case report. J Radiol Case Rep 2015; 9 (09) 36-43
• 122 Al-Nowaylati A-R, Al-Haddad BJS, Dorman RB. , et al. Gastric bypass after liver transplantation. Liver Transpl 2013; 19 (12) 1324-1329
• 123 Suraweera D, Dutson E, Saab S. Liver Transplantation and Bariatric Surgery: Best Approach. Clin Liver Dis 2017; 21 (02) 215-230
• 124 Fink JM, Martini V, Seifert G, Marjanovic G. Left gastric artery embolization for weight loss-a dead-end procedure. Obes Surg 2018; 28 (11) 3623-3624
• 125 Akinwande O, Akinwande O, Holly B. , et al. FEATURED ABSTRACT Recanalization/collateralization after bariatric embolization in a swine model: comparison between 40 μm, 100–300 μm and 300–500 μm embolic microspheres. J Vasc Interv Radiol 2016; 27 (03) S9
• 126 Caine M, Zhang X, Hill M. , et al. Comparison of microsphere penetration with LC Bead LUMI™ versus other commercial microspheres. J Mech Behav Biomed Mater 2018; 78: 46-55
• 127 Weiss CR, Gunn AJ, Kim CY, Paxton BE, Kraitchman DL, Arepally A. Bariatric embolization of the gastric arteries for the treatment of obesity. J Vasc Interv Radiol 2015; 26 (05) 613-624
• 128 Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. Erratum: XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients (Diabetes Care (2004) 27 (155–161)). Diabetes Care 2004; 27 (03) 856
• 129 Smith SR, Weissman NJ, Anderson CM. , et al; Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010; 363 (03) 245-256
• 130 Munro JF, MacCuish AC, Wilson EM, Duncan LJP. Comparison of continuous and intermittent anorectic therapy in obesity. BMJ 1968; 1 (5588): 352-354
• 131 Garvey WT, Ryan DH, Look M. , et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 2012; 95 (02) 297-308
• 132 Pi-Sunyer X, Astrup A, Fujioka K. , et al; SCALE Obesity and Prediabetes NN8022-1839 Study Group. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med 2015; 373 (01) 11-22
• 133 Abu Dayyeh BK, Eaton LL, Woodman G. , et al. 444 A randomized, multi-center study to evaluate the safety and effectiveness of an intragastric balloon as an adjunct to a behavioral modification program, in comparison with a behavioral modification program alone in the weight management of obese subject. Gastrointest Endosc 2015; 81 (5, suppl): AB147
• 134 Ponce J, Woodman G, Swain J. , et al; REDUCE Pivotal Trial Investigators. The REDUCE pivotal trial: a prospective, randomized controlled pivotal trial of a dual intragastric balloon for the treatment of obesity. Surg Obes Relat Dis 2015; 11 (04) 874-881
• 135 Sullivan S, Swain JM, Woodman G. , et al. 812d The obalon swallowable 6-month balloon system is more effective than moderate intensity lifestyle therapy alone: results from a 6- month randomized sham controlled trial. Gastroenterology 2016; 150 (04) (Suppl. 01) S1267
• 136 Nyström M, Machytka E, Norén E. , et al. Aspiration therapy as a tool to treat obesity: 1-to 4-year results in a 201-patient multi-center post-market European registry study. Obes Surg 2018; 28 (07) 1860-1868
• 137 Lopez-Nava G, Sharaiha RZ, Vargas EJ. , et al. Endoscopic Sleeve Gastroplasty for Obesity: a Multicenter Study of 248 Patients with 24 Months Follow-Up. Obes Surg 2017; 27 (10) 2649-2655
• 138 Abu Dayyeh BK, Kumar N, Edmundowicz SA. , et al; ASGE Bariatric Endoscopy Task Force and ASGE Technology Committee. ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies. Gastrointest Endosc 2015; 82 (03) 425-38.e5